Gland Pharma vs Anthem Biosciences vs Ipca Labs: Which Stock Should You Track
- October 8, 2026
- Posted by: Kunal Singla
- Category: Market
Gland Pharma PE 42.62, mkt cap Rs 48,107 crore. Anthem Biosciences PE 85.25, mkt cap Rs 49,081 crore. Ipca Laboratories PE 36.76, mkt cap Rs 50,543 crore.
Quick Answer
Gland Pharma vs Anthem Biosciences vs Ipca Laboratories is a side-by-side comparison of three companies from the Pharma and Biotech space. On this comparison, Gland Pharma carries a market capitalisation of about Rs 48,107 crore against Rs 49,081 crore for Anthem Biosciences and Rs 50,543 crore for Ipca Laboratories, with return on equity of 9.92%, 19.45% and 14.15% respectively. Each company’s numbers are presented here without a declared better pick, since the right stock depends on an investor’s own criteria.
Gland Pharma vs Anthem Biosciences vs Ipca Laboratories starts with the core numbers most investors compare within the Pharma and Biotech segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of October 2026 and will shift with daily price moves.
All three names sit in the Pharma and Biotech bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.
Click Here – Get Free Investment Predictions
Gland Pharma, Anthem Biosciences and Ipca Laboratories: Company Overview
Gland Pharma is a listed Indian company in the Pharma and Biotech space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Anthem Biosciences is a listed Indian company in the Pharma and Biotech space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Ipca Laboratories is a listed Indian company in the Pharma and Biotech space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Gland Pharma vs Anthem Biosciences vs Ipca Laboratories: Valuation and Profitability Snapshot
| Metric | Gland Pharma | Anthem Biosciences | Ipca Laboratories |
|---|---|---|---|
| Market Cap (approx.) | Rs 48,107 crore | Rs 49,081 crore | Rs 50,543 crore |
| PE Ratio (TTM) | 42.62 | 85.25 | 36.76 |
| PB Ratio | 4.64 | 16.13 | 6.27 |
| Return on Equity (ROE) | 9.92% | 19.45% | 14.15% |
| EPS (TTM, Rs) | 68.41 | 10.22 | 54.20 |
| Dividend Yield | 0.69% | 0.23% | 0.30% |
| Debt to Equity | 0.03 | 0.02 | 0.10 |
| Book Value per Share (Rs) | 627.71 | 54.01 | 317.84 |
Check the Univest Screener for Live Data
On valuation, Gland Pharma trades at a PE of 42.62 and a PB of 4.64, Anthem Biosciences at a PE of 85.25 and a PB of 16.13, while Ipca Laboratories trades at a PE of 36.76 and a PB of 6.27. On return on equity, the three post 9.92%, 19.45% and 14.15% respectively, and on dividend yield they stand at 0.69%, 0.23% and 0.30%.
Gland Pharma vs Anthem Biosciences vs Ipca Laboratories: Latest Quarterly Results
| Company | Latest Quarter Revenue | Latest Quarter Net Profit | YoY Change (Revenue) | QoQ Change (Revenue) |
|---|---|---|---|---|
| Gland Pharma | Rs 1,861.50 crore | Rs 316.96 crore | +19.1% | +0.4% |
| Anthem Biosciences | Rs 443.11 crore | Rs 119.94 crore | -21.3% | -33.1% |
| Ipca Laboratories | Rs 2,813.36 crore | Rs 422.81 crore | +20.2% | +13.3% |
Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter.
Download the Univest iOS App or Univest Android App to track Gland Pharma, Anthem Biosciences and Ipca Laboratories live prices.
What Should Investors Look at Beyond These Numbers?
Beyond the metrics above, investors comparing these three pharma and biotech names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and any sector-specific regulatory developments, since a single-quarter snapshot can shift quickly.
Conclusion
Gland Pharma vs Anthem Biosciences vs Ipca Laboratories highlights how differently three companies in the same pharma and biotech segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information as of October 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Gland Pharma vs Anthem Biosciences vs Ipca Laboratories
What is the market cap difference between Gland Pharma, Anthem Biosciences and Ipca Laboratories?
Ans. As of October 2026, Gland Pharma has a market cap of approximately Rs 48,107 crore, Anthem Biosciences is at approximately Rs 49,081 crore, and Ipca Laboratories is at approximately Rs 50,543 crore.
Which of the three has the highest PE ratio?
Ans. Among Gland Pharma, Anthem Biosciences and Ipca Laboratories, the PE ratios stand at 42.62, 85.25 and 36.76 respectively as of October 2026.
Which of the three has the highest ROE?
Ans. Gland Pharma, Anthem Biosciences and Ipca Laboratories post ROE of 9.92%, 19.45% and 14.15% respectively as of October 2026.
Which of these three stocks pays the highest dividend yield?
Ans. Gland Pharma, Anthem Biosciences and Ipca Laboratories carry dividend yields of 0.69%, 0.23% and 0.30% respectively.
What is the debt to equity ratio for Gland Pharma, Anthem Biosciences and Ipca Laboratories?
Ans. Gland Pharma carries a debt to equity of 0.03, Anthem Biosciences of 0.02, and Ipca Laboratories of 0.10.
Which of the three trades at the highest price to book value?
Ans. Gland Pharma, Anthem Biosciences and Ipca Laboratories trade at price to book ratios of 4.64, 16.13 and 6.27 respectively.
Is one of Gland Pharma, Anthem Biosciences or Ipca Laboratories better than the others?
Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor’s own criteria and research.
